Featured Research

from universities, journals, and other organizations

New Class Of Drug Reduces Post-operative Vomiting

Date:
October 26, 2005
Source:
Duke University Medical Center
Summary:
The results of a new Phase III clinical trial have demonstrated that a new class of drugs, called "NK-1 receptor antagonists," is more effective at reducing vomiting after surgery than the most commonly used drug, according to the Duke University Medical Center researchers who led the trial.

ATLANTA -- The results of a new Phase III clinical trial have demonstrated that a new class of drugs, called "NK-1 receptor antagonists," is more effective at reducing vomiting after surgery than the most commonly used drug, according to the Duke University Medical Center researchers who led the trial.

Related Articles


The finding is important, the researchers said, because despite decades of advances in surgical technique and improved anesthetic agents, one out of three patients will still experience nausea and vomiting after surgery. These events not only influence patient satisfaction with their procedure, but can also prolong recovery, lengthen hospital stays and negatively impact the surgery itself, the researchers said.

"There are more than thirty-five million surgical procedures performed each year in the U.S., so postoperative nausea and vomiting is an extremely important health care issue," said Tong Joo (TJ) Gan, M.D., Duke anesthesiologist who led the trial. He presented the results of the trial Oct. 24, 2005, at the annual scientific sessions of the American Society of Anesthesiologists in Atlanta.

"Vomiting is also an issue that most physicians do not take seriously enough -- they see it as a short-term nuisance that will soon pass," Gan said. "However, studies have shown that nausea and vomiting after surgery is the major factor influencing whether or not patients are satisfied with their surgery. When I talk to patients before their surgeries, most are more afraid of the vomiting afterwards than they are of the pain."

"Most of the anti-emetic drugs we have today just aren't that effective in controlling this side effect," Gan continued. "So, an effective drug to treat postoperative vomiting could be a great advance for our patients."

Compared to existing drugs, the NK-1 receptor antagonist blocks at a different site the cascade of biological signals leading to nausea and vomiting. Specifically, 95 percent of patients taking the NK-1 receptor antagonist before surgery did not experience vomiting 24 hours after surgery, compared to 74 percent for the most commonly used drug, ondansetron. The results were similar 48 hours after surgery, 93 percent vs. 67 percent.

"This new drug offers significant advantages in reducing the incidence of vomiting in patients after surgery," said Gan. "This is the first time that an anti-sickness drug provides a sustained protection against postoperative vomiting in more than 90 percent of patients."

While the trial found a significant improvement in the incidence of vomiting, there was little difference between the two drugs in reducing nausea. Also, Gan said, the NK-1 receptor antagonist was well-tolerated by the patients enrolled in the trial.

For the trial, researchers from 30 centers enrolled 805 patients who were receiving general anesthesia for abdominal surgery requiring overnight hospitalization. Patients were randomized to receive either a high or a low dose of the NK-1 receptor antagonist. The NK-1 receptor antagonist was given orally one hour prior to surgery, while ondansetron was administered at the beginning of surgery..

While both groups who received the NK-1 receptor antagonist had significantly higher reductions in vomiting when compared to ondansetron, patients on the higher dose experienced the highest reductions.

The currently used drugs, like ondansetron, block signals in the gut and chemoreceptor trigger zone (CTZ), which is located in the brainstem. Typically, a nausea impulse begins in the CTZ, travels to the vomiting center within the brain, and then on to the stomach, Gan explained.

"However, not only are there NK-1 receptors in the CTZ, they are also present in abundance in the brain's vomiting center," Gan continued. "So while the NK-1 receptor antagonist has an effect on the CTZ, it can also effectively block the impulses farther downstream."

Gan said that future studies will explore combining the NK-1 receptor antagonist with other anti-nausea medications to see if the overall rate of postoperative nausea and vomiting (PONV) can be reduced even more.

According to Gan, patients undergoing certain procedures tend to have higher rates of PONV. For example, more than 70 percent of patients undergoing brain surgery suffer from PONV. Since the act of vomiting can raise the pressure within brain, controlling this side effect is quite important for the medical recovery of these patients, Gan said. The same holds true for patients undergoing surgery of the upper gastrointestinal tract, he added, since the act of vomiting could cause sutures to come apart.

###

The trial was funded by Merck Research Laboratories, the developer of NK-1 receptor antagonist known generically as aprepitant. Gan has no financial interests in Merck.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "New Class Of Drug Reduces Post-operative Vomiting." ScienceDaily. ScienceDaily, 26 October 2005. <www.sciencedaily.com/releases/2005/10/051026090455.htm>.
Duke University Medical Center. (2005, October 26). New Class Of Drug Reduces Post-operative Vomiting. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2005/10/051026090455.htm
Duke University Medical Center. "New Class Of Drug Reduces Post-operative Vomiting." ScienceDaily. www.sciencedaily.com/releases/2005/10/051026090455.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins